{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:02:08Z","timestamp":1791158528567,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>In non-small cell lung cancer (NSCLC), two key genetic alterations, epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>) mutations and anaplastic lymphoma kinase (<jats:italic>ALK<\/jats:italic>) rearrangements, are commonly believed to be mutually exclusive. Studies have reported that concurrent <jats:italic>EGFR\/ALK<\/jats:italic> co-mutation in non-small cell lung cancer patients is rare, with a prevalence ranging from 0.1% to 1.6%. However, the clinical and pathological characteristics of these patients are not well-defined, and the optimal treatment approach for such cases remains controversial. In this report, we present a case of stage IV lung adenocarcinoma with both epidermal growth factor receptor and anaplastic lymphoma kinase mutations, along with high PD-L1 expression. The patient initially received treatment with epidermal growth factor receptor tyrosine kinase inhibitors (TKIs), but the disease progressed. However, following a switch to <jats:italic>ALK<\/jats:italic>-TKI therapy and local radiotherapy, the lesion showed regression. Our report also provides a comprehensive summary of the clinical and pathological features, as well as treatment strategies, for non-small cell lung cancer patients with concurrent epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.<\/jats:p>","DOI":"10.3389\/fphar.2023.1167959","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:05:34Z","timestamp":1693353934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Haoyue","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangrui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1200\/jco.2013.31.15_suppl.8000","article-title":"Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.lungcan.2013.05.003","article-title":"A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene","volume":"81","author":"Chen","year":"2013","journal-title":"Lung cancer (Amsterdam, Neth)."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1200\/JCO.2012.47.7141","article-title":"Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene","volume":"32","author":"Chiari","year":"2014","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10456-021-09811-8","article-title":"Successful management of lung adenocarcinoma with ALK\/EGFR coalterations and PD-L1 overexpression by bevacizumab combined with chemotherapy","volume":"25","author":"He","year":"2022","journal-title":"Angiogenesis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1200\/JCO.2009.23.6661","article-title":"EML4-ALK: honing in on a new target in non-small cell lung cancer","volume":"27","author":"Horn","year":"2009","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1634\/theoncologist.2020-0011","article-title":"Real-world treatment patterns and progression-free survival associated with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor therapies for ALK+ non-small cell lung cancer","volume":"25","author":"Jahanzeb","year":"2020","journal-title":"Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2217\/fon-2021-0195","article-title":"EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in asian populations","volume":"17","author":"Kim","year":"","journal-title":"Future Oncol. Lond. Engl."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2217\/fon-2021-0195","article-title":"EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small cell lung cancer: outcomes in asian populations","volume":"17","author":"Kim","year":"","journal-title":"Future Oncol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.18_suppl.cra7506","article-title":"Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI\u2019s Lung Cancer Mutation Consortium (LCMC)","volume":"29","author":"Kris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1097\/JTO.0b013e3181f43274","article-title":"Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation","volume":"5","author":"Kuo","year":"2010","journal-title":"J. Thorac. Oncol. official Publ. Int. Assoc. Study Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12885-016-2088-5","article-title":"Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report","volume":"16","author":"Liang","year":"2016","journal-title":"BMC cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2147\/DDDT.S196189","article-title":"Frequency, clinical features and differential response to therapy of concurrent ALK\/EGFR alterations in Chinese lung cancer patients","volume":"13","author":"Liu","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"59889","DOI":"10.18632\/oncotarget.17431","article-title":"Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases","volume":"8","author":"Lo Russo","year":"2017","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","first-page":"65185","DOI":"10.18632\/oncotarget.11218","article-title":"Clinical outcomes of advanced non-small cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR\/ALK coalterations","volume":"7","author":"Lou","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.2147\/OTT.S294635","article-title":"Egfr (p. G719A+L747V)\/EML4-ALK coalterations in lung adenocarcinoma with leptomeningeal metastasis responding to Afatinib treatment: a case report","volume":"14","author":"Lu","year":"2021","journal-title":"OncoTargets Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.2147\/OTT.S133349","article-title":"ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma","volume":"10","author":"Mao","year":"2017","journal-title":"OncoTargets Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/1471-2407-13-262","article-title":"Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small cell lung cancer harbored coexisting EGFR mutation","volume":"13","author":"Miyanaga","year":"2013","journal-title":"BMC cancer"},{"key":"B18","first-page":"1","article-title":"EGFRLung cancer with dual and driver alterations at baseline: a retrospective observational cohort study","author":"Noronha","year":"2022","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Sci. (New York, NY)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1097\/JTO.0b013e31822eec5e","article-title":"Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib","volume":"6","author":"Popat","year":"2011","journal-title":"J. Thorac. Oncol. official Publ. Int. Assoc. Study Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.lungcan.2013.04.009","article-title":"Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib","volume":"81","author":"Santelmo","year":"2013","journal-title":"Lung cancer (Amsterdam, Neth."},{"key":"B22","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jtho.2016.12.003","article-title":"Clinical outcome of ALK-positive non-small cell lung cancer (NSCLC) patients with de novo EGFR or KRAS Co-mutations receiving tyrosine kinase inhibitors (TKIs)","volume":"12","author":"Schmid","year":"2017","journal-title":"J. Thorac. Oncol. official Publ. Int. Assoc. Study Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e14699","DOI":"10.1097\/MD.0000000000014699","article-title":"Coalteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: case series","volume":"98","author":"Shin","year":"2019","journal-title":"Medicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/1471-2407-12-558","article-title":"A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene","volume":"12","author":"Tanaka","year":"2012","journal-title":"BMC cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.lungcan.2010.11.014","article-title":"EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations","volume":"71","author":"Tiseo","year":"2011","journal-title":"Lung cancer (Amsterdam, Neth."},{"key":"B28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cllc.2015.11.004","article-title":"Nonsquamous, non-small cell lung cancer patients who Carry a Double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy","volume":"17","author":"Ulivi","year":"2016","journal-title":"Clin. lung cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/annonc\/mdu530","article-title":"Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor","volume":"26","author":"Won","year":"2015","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.3892\/mmr.2015.4001","article-title":"A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: a case report and literature review","volume":"12","author":"Xu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-0699","article-title":"Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation","volume":"20","author":"Yang","year":"2014","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.cllc.2014.11.001","article-title":"Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review","volume":"16","author":"Zhao","year":"2015","journal-title":"Clin. lung cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/1759-7714.12146","article-title":"Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement","volume":"6","author":"Zhou","year":"2015","journal-title":"Thorac. cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40246-021-00320-9","article-title":"Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC)","volume":"15","author":"Zhou","year":"2021","journal-title":"Hum. genomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1167959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:05:36Z","timestamp":1693353936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1167959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":34,"alternative-id":["10.3389\/fphar.2023.1167959"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1167959","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"article-number":"1167959"}}